← Leaderboards
Eric S Daar
La Biomed Res Inst/ Harbor Ucla Med Ctr
$9,910,615
Attributed
$13,567,620
Total exposure
37
Grants
28
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,567,620 · 37
By mechanism
R01$7,314,010 · 2
M01$6,253,610 · 35
Top collaborators
- Honghu Liu8 shared
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelUnited States National Institutes Of HealthFundingInstitutionGrantSourceComputer Retrieval Of Information On Scientific Projects DatabaseResourcesPharmaceutical PreparationsHiv InfectionsViral Load ResultEventClinical ResearchRandomizedTissuesBrainAntiretroviral TherapyMonitorPlasmaAnti-Retroviral AgentsCaliforniaNeurologicPersonsHuman Subject
Grant awards (49)
An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH$1,138,343
R01 · FY2025 · MD
An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH$1,151,751
R01 · FY2024 · MD
An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH$1,025,878
R01 · FY2023 · MD
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System$679,777
R01 · FY2019 · MH
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System$884,125
R01 · FY2018 · MH
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System$882,370
R01 · FY2017 · MH
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System$879,497
R01 · FY2016 · MH
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System$672,269
R01 · FY2015 · MH
CLINICAL TRIAL: A PHASE III COMPARATIVE STUDY OF THREE NON-NUCLEOSIDE REVERSE TR$199,155
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZA$175,597
M01 · FY2010 · RR · contact PI
A LONGITUDINAL STUDY OF CEREBRAL AND NEUROCOGNITIVE FUNCTION$167,033
M01 · FY2010 · RR · contact PI
CALIFORNIA NEUROAIDS TISSUE NETWORK (CNTN)$111,353
M01 · FY2010 · RR · contact PI
CALIFORNIA NEURO AIDS TISSUE NETWORK$100,650
M01 · FY2010 · RR · contact PI
LONG-TERM METABOLIC ASSESSMENTS IN SUBJECTS TREATED WITH EMTRICITABINE/TENOFO$53,534
M01 · FY2010 · RR · contact PI
CALIFORNIA NEURO AIDS TISSUE NETWORK$121,058
M01 · FY2009 · RR · contact PI
A LONGITUDINAL STUDY OF CEREBRAL AND NEUROCOGNITIVE FUNCTION$99,875
M01 · FY2009 · RR · contact PI
LONG-TERM METABOLIC ASSESSMENTS IN SUBJECTS TREATED WITH EMTRICITABINE/TENOFO$63,557
M01 · FY2009 · RR · contact PI
A PHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIA$9,080
M01 · FY2009 · RR · contact PI
PATHOGENESIS OF PRIMARY HIV INFECTION$480,220
M01 · FY2008 · RR · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$428,895
M01 · FY2008 · RR · contact PI
LONG-TERM METABOLIC ASSESSMENTS IN SUBJECTS TREATED WITH EMTRICITABINE/TENOFO$128,306
M01 · FY2008 · RR · contact PI
CALIFORNIA NEURO AIDS TISSUE NETWORK$106,311
M01 · FY2008 · RR · contact PI
CALIFORNIA NEURO - AIDS TISSUE NETWORK$25,657
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIA$18,333
M01 · FY2008 · RR · contact PI
PATHOGENESIS OF PRIMARY HIV INFECTION$453,757
M01 · FY2007 · RR · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$443,294
M01 · FY2007 · RR · contact PI
CALIFORNIA NEURO - AIDS TISSUE NETWORK$45,768
M01 · FY2007 · RR · contact PI
LONG-TERM METABOLIC ASSESSMENTS IN SUBJECTS TREATED WITH EMTRICITABINE/TENOFO$30,078
M01 · FY2007 · RR · contact PI
CALIFORNIA NEURO AIDS TISSUE NETWORK$16,999
M01 · FY2007 · RR · contact PI
THE SETPOINT STUDY - A RANDOMIZED STUDY OF THE EFFECT OF IMMEDIATE TREATMENT$3,072
M01 · FY2007 · RR · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL, COMPARISON OF LOPINAVIR/RITONAVIR PLUS E$1,307
M01 · FY2007 · RR · contact PI
PATHOGENESIS OF PRIMARY HIV INFECTION$532,021
M01 · FY2006 · RR · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$511,497
M01 · FY2006 · RR · contact PI
CALIFORNIA NEURO - AIDS TISSUE NETWORK$95,800
M01 · FY2006 · RR · contact PI
CALIFORNIA NEURO AIDS TISSUE NETWORK$35,924
M01 · FY2006 · RR · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL, COMPARISON OF LOPINAVIR/RITONAVIR PLUS E$25,660
M01 · FY2006 · RR · contact PI
PATHOGENESIS OF PRIMARY HIV INFECTION$612,874
M01 · FY2005 · RR
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$165,421
M01 · FY2005 · RR
CALIFORNIA NEURO - AIDS TISSUE NETWORK$121,041
M01 · FY2005 · RR
CALIFORNIA NEURO AIDS TISSUE NETWORK$56,484
M01 · FY2005 · RR
A PHASE III, RANDOMIZED, OPEN-LABEL, COMPARISON OF LOPINAVIR/RITONAVIR PLUS E$34,297
M01 · FY2005 · RR
Pathogenesis of Primary HIV Infection$400,787
M01 · FY2004 · RR
California Neuro - AIDS Tissue Network$73,476
M01 · FY2004 · RR
CALIFORNIA NEURO AIDS TISSUE NETWORK$55,982
M01 · FY2004 · RR
PHASE III, RANDOMIZED, OPEN-LABEL, COMPARISON OF LOPIN$10,497
M01 · FY2004 · RR
PATHOGENESIS OF PRIMARY HIV INFECTION$237,978
M01 · FY2001 · RR
PATHOGENESIS OF PRIMARY HIV INFECTION$982
M01 · FY2000 · RR
PATHOGENESIS OF PRIMARY HIV INFECTION$0
M01 · FY2000 · RR
PATHOGENESIS OF PRIMARY HIV INFECTION$0
M01 · FY2000 · RR